Primary vs Secondary Closure of Tracheo-cutaneous Fistulas
Launched by UNIVERSITÉ DE SHERBROOKE · Nov 23, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating two different methods for closing a tracheo-cutaneous fistula, which is an opening that can develop after a tracheostomy (a procedure where a tube is placed in the windpipe to help with breathing). The trial aims to compare "primary closure," where the opening is closed right away, and "secondary closure," where the opening is allowed to heal over time before being closed. By studying these methods, researchers hope to find out which technique leads to better outcomes for patients.
To participate in this trial, individuals must be between 65 and 74 years old, have a tracheostomy (either done through the skin or surgically), and be ready to have their tube removed and the fistula closed. It's important to note that those with certain conditions that would prevent immediate closure or who are unable to give consent cannot join the study. Participants can expect to receive care and monitoring as they undergo either of the closure methods, helping to contribute valuable information that could improve treatment for others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Being covered by the RAMQ
- • Having a tracheostomy either percutaneous or surgical
- • Being ready for canula removal and closure of the fistula
- Exclusion Criteria:
- • Presenting a contraindication to primary tracheotomy closure (granuloma)
- • Unable to consent
- • Refusal to participate
About Université De Sherbrooke
The Université de Sherbrooke is a leading research institution in Canada, renowned for its commitment to advancing knowledge and innovation in various fields, including health sciences. With a focus on interdisciplinary collaboration, the university actively engages in clinical trials to explore new therapeutic interventions and improve patient care. Its research team comprises experienced professionals dedicated to ensuring the highest ethical standards and scientific rigor in clinical research. The Université de Sherbrooke strives to translate research findings into practical solutions that enhance health outcomes and contribute to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sherbrooke, Quebec, Canada
Patients applied
Trial Officials
Simon Brisebois, MD, MSC
Principal Investigator
Université de Sherbrooke
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials